Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Axsome Therapeutics Q2 2024 Adj. EPS $(1.12) Beats $(1.34) Estimate

Author: Benzinga Newsdesk | August 05, 2024 07:12am

Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(1.12) per share which beat the analyst consensus estimate of $(1.34) by 16.42 percent. 

Posted In: AXSM


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist